$-0.05 EPS Expected for CytoDyn Inc (CYDY)

September 17, 2017 - By Dolores Ford

 $ 0.05 EPS Expected for CytoDyn Inc (CYDY)

Analysts expect CytoDyn Inc (OTCMKTS:CYDY) to report $-0.05 EPS on October, 11.They anticipate $0.01 EPS change or 25.00 % from last quarter’s $-0.04 EPS. The stock increased 7.51% or $0.045 on September 15, reaching $0.645. About 86,420 shares traded. CytoDyn Inc (OTCMKTS:CYDY) has 0.00% since September 17, 2016 and is . It has underperformed by 16.70% the S&P500.

CytoDyn Inc. is a clinical-stage biotechnology company. The company has market cap of $100.69 million. The Firm is focused on the clinical development and commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus infection. It currently has negative earnings. The Company’s lead product candidate, PRO 140, belongs to a class of HIV therapies known as entry inhibitors that block HIV from entering into and infecting certain cells.

More news for CytoDyn Inc (OTCMKTS:CYDY) were recently published by: Seekingalpha.com, which released: “Cytodyne’s PRO 140: Better Safety, Non-Inferior Efficacy In HIV” on November 30, 2015. Marketwatch.com‘s article titled: “0.6451” and published on April 14, 2011 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.